XELPROS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Xelpros, and when can generic versions of Xelpros launch?
Xelpros is a drug marketed by Sun Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has nineteen patent family members in seventeen countries.
The generic ingredient in XELPROS is latanoprost. There are twenty drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the latanoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Xelpros
A generic version of XELPROS was approved as latanoprost by AMRING PHARMS on March 22nd, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XELPROS?
- What are the global sales for XELPROS?
- What is Average Wholesale Price for XELPROS?
Summary for XELPROS
| International Patents: | 19 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 6,239 |
| Drug Prices: | Drug price information for XELPROS |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for XELPROS |
| What excipients (inactive ingredients) are in XELPROS? | XELPROS excipients list |
| DailyMed Link: | XELPROS at DailyMed |
Pharmacology for XELPROS
| Drug Class | Prostaglandin Analog |
US Patents and Regulatory Information for XELPROS
XELPROS is protected by two US patents.
Patents protecting XELPROS
Ophthalmic composition comprising a prostaglandin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Ophthalmic composition comprising a prostaglandin
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm | XELPROS | latanoprost | EMULSION;OPHTHALMIC | 206185-001 | Sep 12, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sun Pharm | XELPROS | latanoprost | EMULSION;OPHTHALMIC | 206185-001 | Sep 12, 2018 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for XELPROS
See the table below for patents covering XELPROS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Africa | 201002615 | OPHTHALMIC COMPOSITION COMPRISING A PROSTAGLANDIN | ⤷ Sign Up |
| Israel | 205095 | ⤷ Sign Up | |
| Japan | 2011508724 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for XELPROS
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3461484 | SPC/GB21/033 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF LATANOPROST AND NETARSUDIL; REGISTERED: UK EU/1/20/1502(FOR NI) 20210107; UK PLGB 16053/0034 20210107 |
| 3461484 | 301101 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
| 0364417 | SPC/GB97/014 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
